WebGemtesa contraindications. GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product [see Adverse Reactions (6.2) ] . Do not use if prior hypersensitivity reaction to vibegron or any components of the product. ( 4 ) Gemtesa during pregnancy WebGemtesa is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. Clinical Efficacy (3,4,5) (mechanism of action/pharmacology, comparative efficacy) Gemtesa is a selective human beta-3 adrenergic receptor agonist. Activation of the beta-3
FDA Approvals Roundup: Gemtesa RAPS
WebThe most common side effects of GEMTESA include headache, urinary tract infection, nasal congestion, sore throat or runny nose, diarrhea, nausea and upper respiratory tract infection. These are not all the possible side … WebFeb 11, 2024 · Concomitant use of GEMTESA increases digoxin maximal concentrations (C max) and systemic exposure as assessed by area under the concentration-time curve … crik crok originali neutre
GEMTESA Healthgrades (vibegron tablet, film coated)
WebMay 2, 2024 · You should not use Gemtesa if you are allergic to vibegron. To make sure Gemtesa is safe for you, tell your doctor if you have ever had: trouble emptying your bladder; a weak stream of urine; liver disease; or kidney disease. Tell your doctor if you … The recommended dosage of GEMTESA is one 75 mg tablet orally, once daily with … Gemtesa has an average rating of 5.9 out of 10 from a total of 44 ratings on … Gemtesa Simple Savings Card: Eligible commercially insured patients may pay … Other adverse reactions reported in <2% of patients treated with Gemtesa included: … WebCONTRAINDICATIONS GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product. WARNINGS AND … WebVibegron (Gemtesa) • Diagnosis of dementia or receiving medications indicated for dementia (e.g., acetylcholinesterase inhibitors or NMDA receptor antagonists)-OR- • If patient is less than 64 years old: Documented treatment failure, intolerance*, or contraindication to at least two (2) cri iturama